This work is licensed under the Creative Commons Attribution 4.0 International License.
D. Tomasoni, M. Adamo M, C.M. Lombardi, M. Metra, “Highlights in heart failure”, ESC Heart Fail, vol. 6 no. 6, pp. 1105–1127, Dec 2019. doi: 10.1002/ehf2.12555 PMID: 31997538 PMCID: PMC6989277TomasoniD.Adamo MM.LombardiC.M.MetraM.“Highlights in heart failure”ESC Heart Fail6611051127Dec201910.1002/ehf2.12555PMID: 31997538 PMCID: PMC6989277698927731997538Open DOISearch in Google Scholar
D. Tomasoni, M. Adamo, M.S. Anker, S. von Haehling, A.J.S. Coats, M. Metra, “Heart failure in the last year: progress and perspective”, ESC Heart Fail, vol. 7 no. 6, pp. 3505–3530, 2020. doi: 10.1002/ehf2.13124 PMID: 33277825 PMCID: PMC7754751TomasoniD.AdamoM.AnkerM.S.von HaehlingS.CoatsA.J.S.MetraM.“Heart failure in the last year: progress and perspective”ESC Heart Fail7635053530202010.1002/ehf2.13124PMID: 33277825 PMCID: PMC7754751775475133277825Open DOISearch in Google Scholar
L. Stretti, D. Zippo, A.J.S. Coats, M.S. Anker, S. von Haehling, M. Metra, D. Tomasoni “A year in heart failure: an update of recent findings”, ESC Heart Fail, vol. 8 no. 6, pp. 4370–4393, December 2021. doi: 10.1002/ehf2.13760 PMID: 34918477 PMCID: PMC9073717StrettiL.ZippoD.CoatsA.J.S.AnkerM.S.von HaehlingS.MetraM.TomasoniD.“A year in heart failure: an update of recent findings”ESC Heart Fail8643704393December202110.1002/ehf2.13760PMID: 34918477 PMCID: PMC9073717907371734918477Open DOISearch in Google Scholar
T.A. McDonagh, M. Metra, M.Adamo, R.S. Gardner, A. Baumbach, M. Böhm, H. Burri, J. Butler, J. Čelutkienė, O. Chioncel, et al., “2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC”, Eur. Heart J., 42, pp. 3599–3726, 2021.McDonaghT.A.MetraM.AdamoM.GardnerR.S.BaumbachA.BöhmM.BurriH.ButlerJ.ČelutkienėJ.ChioncelO.“2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC”Eur. Heart J.4235993726202110.1016/j.rec.2022.05.00535636830Search in Google Scholar
A.N. Emara, N.O. Mansour, M.H. Elnaem, M. Wadie, I.S. Dehele, M.E.E. Shams, “Efficacy of Nondiuretic Pharmacotherapy for Improving the Treatment of Congestion in Patients with Acute Heart Failure: A Systematic Review of Randomised Controlled Trials”, J Clin Med., vol. 11 no. 11, p. 3112, May 2022. doi: 10.3390/jcm11113112 PMID: 35683505 PMCID: PMC9181246EmaraA.N.MansourN.O.ElnaemM.H.WadieM.DeheleI.S.ShamsM.E.E.“Efficacy of Nondiuretic Pharmacotherapy for Improving the Treatment of Congestion in Patients with Acute Heart Failure: A Systematic Review of Randomised Controlled Trials”J Clin Med.11113112May202210.3390/jcm11113112PMID: 35683505 PMCID: PMC9181246918124635683505Open DOISearch in Google Scholar
A. Cahn, O. Mosenzon, S.D. Wiviott, A. Rozenberg, I. Yanuv, E.L. Goodrich, S.A. Murphy, D.L. Bhatt, L.A. Leiter, D.K. McGuire, J.P.H. Wilding, I.A.M. Gause-Nilsson, M. Fredriksson, P.A. Johansson, A.M. Langkilde, M.S. Sabatine, I. Raz, “Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study”, Diabetes Care, vol. 43 no. 2, pp. 468–475, December 2019. doi: 10.2337/dc19-1476. Epub 2019 Dec 16. PMID: 31843945.CahnA.MosenzonO.WiviottS.D.RozenbergA.YanuvI.GoodrichE.L.MurphyS.A.BhattD.L.LeiterL.A.McGuireD.K.WildingJ.P.H.Gause-NilssonI.A.M.FredrikssonM.JohanssonP.A.LangkildeA.M.SabatineM.S.RazI.“Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study”Diabetes Care432468475December201910.2337/dc19-1476Epub 2019 Dec 16. PMID: 31843945.31843945Open DOISearch in Google Scholar
L.M. Pérez-Belmonte, J. Sanz-Cánovas, M. Millán-Gómez, J. Osuna-Sánchez, A. López-Sampalo, M. Ricci, M. Jiménez-Navarro, M.D. López-Carmona, M.R. Bernal-López, M.A. Barbancho, J.P. Lara, R. Gómez-Huelgas, “Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure”, J Am Geriatr Soc., vol. 70 no. 3, pp. 862–871, November 2021. doi: 10.1111/jgs.17585 PMID: 34843628Pérez-BelmonteL.M.Sanz-CánovasJ.Millán-GómezM.Osuna-SánchezJ.López-SampaloA.RicciM.Jiménez-NavarroM.López-CarmonaM.D.Bernal-LópezM.R.BarbanchoM.A.LaraJ.P.Gómez-HuelgasR.“Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure”J Am Geriatr Soc.703862871November202110.1111/jgs.17585PMID: 3484362834843628Open DOISearch in Google Scholar
F. Ilyas, L. Jones, S.L. Tee, M. Horsfall, A. Swan, F. Wollaston, T. Hecker, C. De Pasquale, S. Thomas, W. Chong, S. Stranks, A.A. Mangoni, J.B. Selvanayagam, D.P. Chew, C.G. De Pasquale. “Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial”, ESC Heart Fail., vol. 8 no. 5, pp. 4346–4352, August 2021. doi: 10.1002/ehf2.13553 PMID: 34382353 PMCID: PMC8497349IlyasF.JonesL.TeeS.L.HorsfallM.SwanA.WollastonF.HeckerT.De PasqualeC.ThomasS.ChongW.StranksS.MangoniA.A.SelvanayagamJ.B.ChewD.P.De PasqualeC.G.“Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial”ESC Heart Fail.8543464352August202110.1002/ehf2.13553PMID: 34382353 PMCID: PMC8497349849734934382353Open DOISearch in Google Scholar
D. Kolijn, S, Pabel, Y. Tian, M. Lódi, M. Herwig, A. Carrizzo, S. Zhazykbayeva, Á. Kovács, G.Á. Fülöp, I. Falcão-Pires, P.H. Reusch, S.V. Linthout, Z. Papp, L. van Heerebeek, C. Vecchione, L.S. Maier, M. Ciccarelli, C. Tschöpe, A. Mügge, Z. Bagi, S. Sossalla, N. Hamdani, “Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation”, Cardiovasc Res., vol. 117 no. 2, pp. 495–507, January 2021. doi: 10.1093/cvr/cvaa123 PMID: 32396609KolijnD.PabelSTianY.LódiM.HerwigM.CarrizzoA.ZhazykbayevaS.KovácsÁ.FülöpG.Á.Falcão-PiresI.ReuschP.H.LinthoutS.V.PappZ.van HeerebeekL.VecchioneC.MaierL.S.CiccarelliM.TschöpeC.MüggeA.BagiZ.SossallaS.HamdaniN.“Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation”Cardiovasc Res.1172495507January202110.1093/cvr/cvaa123PMID: 3239660932396609Open DOISearch in Google Scholar
T. Koufakis, O.G. Mustafa, R.A. Ajjan, X. Garcia-Moll, P. Zebekakis, G. Dimitriadis, K. Kotsa, “From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients”, Drugs, vol. 82 no. 9 pp. 949–955, June 2022. doi: 10.1007/s40265-022-01730-2 PMID: 35678922 PMCID: PMC9178534KoufakisT.MustafaO.G.AjjanR.A.Garcia-MollX.ZebekakisP.DimitriadisG.KotsaK.“From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients”Drugs829949955June202210.1007/s40265-022-01730-2PMID: 35678922 PMCID: PMC9178534917853435678922Open DOISearch in Google Scholar
A. Groenewegen, F.H. Rutten, “Sodium-glucose co-transporter 2 inhibitors and acute heart failure”, Eur J Heart Fail, vol. 2 no. 4, pp. 723–725, April 2020. doi: 10.1002/ejhf.1759 PMID: 32072715GroenewegenA.RuttenF.H.“Sodium-glucose co-transporter 2 inhibitors and acute heart failure”Eur J Heart Fail24723725April202010.1002/ejhf.1759PMID: 3207271532072715Open DOISearch in Google Scholar
K. Thiele, M. Rau, N.K. Hartmann, M. Möller, J. Möllmann, J. Jankowski, A.P. Keszei, M. Böhm, J. Floege, N. Marx, M. Lehrke, “Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure”, ESC Heart Fail, vol. 9 no. 4, pp. 2233–2238, May 2022. doi: 10.1002/ehf2.13955. PMID: 35611683 PMCID: PMC9288802ThieleK.RauM.HartmannN.K.MöllerM.MöllmannJ.JankowskiJ.KeszeiA.P.BöhmM.FloegeJ.MarxN.LehrkeM.“Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure”ESC Heart Fail9422332238May202210.1002/ehf2.13955PMID: 35611683 PMCID: PMC9288802928880235611683Open DOISearch in Google Scholar
V. Rotbain Curovic, M.B. Houlind, T.W. Hansen, J. Eugen-Olsen, J.C. Laursen, M.K. Eickhoff, F. Persson, P. Rossing, “Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor”, Front Pharmacol, 27, 13, 799915, April 2022. doi: 10.3389/fphar.2022.799915 PMID: 35571091 PMCID: PMC9091812Rotbain CurovicV.HoulindM.B.HansenT.W.Eugen-OlsenJ.LaursenJ.C.EickhoffM.K.PerssonF.RossingP.“Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor”Front Pharmacol2713799915April202210.3389/fphar.2022.799915PMID: 35571091 PMCID: PMC9091812909181235571091Open DOISearch in Google Scholar
G. Savarese, N. Sattar, J. Januzzi, S. Verma, L.H. Lund, D. Fitchett, C. Zeller, J.T. George, M. Brueckmann, A.P. Ofstad, S.E. Inzucchi, C. Wanner, B. Zinman, J. Butler, “Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality”, Circulation, vol. 139, no. 11, pp. 1458–1460, March 2019. doi: 10.1161/CIRCULATIONAHA.118.038339 PMID: 30855996SavareseG.SattarN.JanuzziJ.VermaS.LundL.H.FitchettD.ZellerC.GeorgeJ.T.BrueckmannM.OfstadA.P.InzucchiS.E.WannerC.ZinmanB.ButlerJ.“Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality”Circulation1391114581460March201910.1161/CIRCULATIONAHA.118.038339PMID: 3085599630855996Open DOISearch in Google Scholar
D.L. Bhatt, M. Szarek, P.G. Steg, C.P. Cannon, L.A. Leiter, D.K. McGuire, J.B. Lewis, M.C. Riddle, A.A. Voors, M. Metra, L.H. Lund, M. Komajda, J.M. Testani, C.S. Wilcox, P. Ponikowski, R.D. Lopes, S. Verma, P. Lapuerta, B. Pitt, “SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure”, N Engl J Med, vol. 384 no. 2, pp.117–128, Jan 2021. doi: 10.1056/NEJMoa2030183 PMID: 33200892BhattD.L.SzarekM.StegP.G.CannonC.P.LeiterL.A.McGuireD.K.LewisJ.B.RiddleM.C.VoorsA.A.MetraM.LundL.H.KomajdaM.TestaniJ.M.WilcoxC.S.PonikowskiP.LopesR.D.VermaS.LapuertaP.PittB.“SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure”N Engl J Med3842117128Jan202110.1056/NEJMoa2030183PMID: 3320089233200892Open DOISearch in Google Scholar
A.A. Voors, C.E. Angermann, J.R. Teerlink, S.P. Collins, M. Kosiborod, J. Biegus, J.P. Ferreira, M.E. Nassif, M.A. Psotka, J. Tromp, C.J.W. Borleffs, C. Ma, J. Comin-Colet, M. Fu, S.P. Janssens, R.G. Kiss, R.J. Mentz, Y. Sakata, H. Schirmer, M. Schou, P.C. Schulze, L. Spinarova, M. Volterrani, J.K. Wranicz, U. Zeymer, S. Zieroth, M. Brueckmann, J.P. Blatchford, A. Salsali, P. Ponikowski, “The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial”, Nat Med, vol. 28 no. 3, pp. 568–574, February 2022. doi: 10.1038/s41591-021-01659-1 PMID: 35228754 PMCID: PMC8938265VoorsA.A.AngermannC.E.TeerlinkJ.R.CollinsS.P.KosiborodM.BiegusJ.FerreiraJ.P.NassifM.E.PsotkaM.A.TrompJ.BorleffsC.J.W.MaC.Comin-ColetJ.FuM.JanssensS.P.KissR.G.MentzR.J.SakataY.SchirmerH.SchouM.SchulzeP.C.SpinarovaL.VolterraniM.WraniczJ.K.ZeymerU.ZierothS.BrueckmannM.BlatchfordJ.P.SalsaliA.PonikowskiP.“The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial”Nat Med283568574February202210.1038/s41591-021-01659-1PMID: 35228754 PMCID: PMC8938265893826535228754Open DOISearch in Google Scholar
M.N. Kosiborod, C.E. Angermann, S.P. Collins, J.R. Teerlink, P. Ponikowski, J. Biegus, J. Comin-Colet, J.P. Ferreira, R.J. Mentz, M.E. Nassif, M.A. Psotka, J. Tromp, M. Brueckmann, J.P. Blatchford, A. Salsali, A.A. Voors, “Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial”, vol. 146 no. 4, pp. 279–288, April 2022. doi: 10.1161/CIRCULATIONAHA.122.059725 PMID: 35377706 PMCID: PMC9311476KosiborodM.N.AngermannC.E.CollinsS.P.TeerlinkJ.R.PonikowskiP.BiegusJ.Comin-ColetJ.FerreiraJ.P.MentzR.J.NassifM.E.PsotkaM.A.TrompJ.BrueckmannM.BlatchfordJ.P.SalsaliA.VoorsA.A.“Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial”1464279288April202210.1161/CIRCULATIONAHA.122.059725PMID: 35377706 PMCID: PMC9311476931147635377706Open DOISearch in Google Scholar
S. Tamaki, T. Yamada, T. Watanabe, T. Morita, Y. Furukawa, M. Kawasaki, A. Kikuchi, T. Kawai, M. Seo, M. Abe, J. Nakamura, K. Yamamoto, K. Kayama, M. Kawahira, K. Tanabe, K. Fujikawa, M. Hata, Y. Fujita, Y. Umayahara, S. Taniuchi, S. Sanada, A. Shintani, M. Fukunami, “Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study”, Circ Heart Fail, vol. 14 no. 3, March 2021. doi: 10.1161/CIRCHEARTFAILURE.120.007048. Erratum in: Circ Heart Fail, vol. 14 no. 4, April 2021. PMID: 33663235TamakiS.YamadaT.WatanabeT.MoritaT.FurukawaY.KawasakiM.KikuchiA.KawaiT.SeoM.AbeM.NakamuraJ.YamamotoK.KayamaK.KawahiraM.TanabeK.FujikawaK.HataM.FujitaY.UmayaharaY.TaniuchiS.SanadaS.ShintaniA.FukunamiM.“Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study”Circ Heart Fail143March202110.1161/CIRCHEARTFAILURE.120.007048Erratum in: Circ Heart Fail, vol. 14 no. 4, April 2021. PMID: 3366323533663235Open DOISearch in Google Scholar
E.M. Boorsma, J.C. Beusekamp, J.M. Ter Maaten, S.M. Figarska, A.H.J. Danser, D.J. van Veldhuisen, P. van der Meer, H.J.L. Heerspink, K. Damman, A.A. Voors, “Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure”, Eur J Heart Fail, vol. 23 no. 1, pp. 68–78, Dec 2020. doi: 10.1002/ejhf.2066 PMID: 33251643 PMCID: PMC8048437BoorsmaE.M.BeusekampJ.C.Ter MaatenJ.M.FigarskaS.M.DanserA.H.J.van VeldhuisenD.J.van der MeerP.HeerspinkH.J.L.DammanK.VoorsA.A.“Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure”Eur J Heart Fail2316878Dec202010.1002/ejhf.2066PMID: 33251643 PMCID: PMC8048437804843733251643Open DOISearch in Google Scholar
K. Damman, J.C. Beusekamp, E.M. Boorsma, H.P. Swart, T.D.J. Smilde, A. Elvan, J.W.M. van Eck, H.J.L. Heerspink, A.A. Voors, “Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)”, Eur J Heart Fail, vol. 22 no. 4, pp. 713–722, Jan 2020. doi: 10.1002/ejhf.1713 PMID: 31912605DammanK.BeusekampJ.C.BoorsmaE.M.SwartH.P.SmildeT.D.J.ElvanA.van EckJ.W.M.HeerspinkH.J.L.VoorsA.A.“Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)”Eur J Heart Fail224713722Jan202010.1002/ejhf.1713PMID: 3191260531912605Open DOISearch in Google Scholar
K.M. Hallow, G. Helmlinger, P.J. Greasley, J.J.V. McMurray, D.W. Boulton, “Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis”, Diabetes Obes Metab, vol. 20 no. 3, pp. 479–487, Nov 2017. doi: 10.1111/dom.13126 PMID: 29024278HallowK.M.HelmlingerG.GreasleyP.J.McMurrayJ.J.V.BoultonD.W.“Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis”Diabetes Obes Metab203479487Nov201710.1111/dom.13126PMID: 2902427829024278Open DOISearch in Google Scholar
K. Charaya, D. Shchekochikhin, D. Andreev, I. Dyachuk, S. Tarasenko, M. Poltavskaya, D. Mesitskaya, A. Bogdanova, N. Ananicheva, A. Kuzub, “Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study”, Open Heart, vol. 9 no. 1, May 2022. doi: 10.1136/openhrt-2021-001936 PMID: 35609943; PMCID: PMC9131063CharayaK.ShchekochikhinD.AndreevD.DyachukI.TarasenkoS.PoltavskayaM.MesitskayaD.BogdanovaA.AnanichevaN.KuzubA.“Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study”Open Heart91May202210.1136/openhrt-2021-001936PMID: 35609943; PMCID: PMC9131063913106335609943Open DOISearch in Google Scholar
B.J. Kraus, M.R. Weir, G.L. Bakris, M. Mattheus, D.Z.I. Cherney, N. Sattar, H.J.L. Heerspink, I. Ritter, M. von Eynatten, B. Zinman, S.E. Inzucchi, C. Wanner, A. Koitka-Weber, “Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial”, Kidney Int, vol. 99 no. 3, pp. 750–762, Mar 2021. doi: 10.1016/j.kint.2020.10.031 PMID: 33181154KrausB.J.WeirM.R.BakrisG.L.MattheusM.CherneyD.Z.I.SattarN.HeerspinkH.J.L.RitterI.von EynattenM.ZinmanB.InzucchiS.E.WannerC.Koitka-WeberA.“Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial”Kidney Int993750762Mar202110.1016/j.kint.2020.10.031PMID: 3318115433181154Open DOISearch in Google Scholar
L.M. Pérez-Belmonte, M. Ricci, J. Sanz-Cánovas, M. Millán-Gómez, J. Osuna-Sánchez, M.I. Ruiz-Moreno, M.R. Bernal-López, M.D. López-Carmona, M. Jiménez-Navarro, J.J. Gómez-Doblas, J.P. Lara, R. Gómez-Huelgas, “Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure”, J Clin Med, vol. 10 no. 16, p. 3540, August 2021. doi: 10.3390/jcm10163540 PMID: 34441835 PMCID: PMC8396978Pérez-BelmonteL.M.RicciM.Sanz-CánovasJ.Millán-GómezM.Osuna-SánchezJ.Ruiz-MorenoM.I.Bernal-LópezM.R.López-CarmonaM.D.Jiménez-NavarroM.Gómez-DoblasJ.J.LaraJ.P.Gómez-HuelgasR.“Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure”J Clin Med10163540August202110.3390/jcm10163540PMID: 34441835 PMCID: PMC8396978839697834441835Open DOISearch in Google Scholar
R.H.M. Furtado, I. Raz, E.L. Goodrich, S.A. Murphy, D.L. Bhatt, L.A. Leiter, D.K. McGuire, J.P.H. Wilding, P. Aylward, A.J. Dalby, M. Dellborg, D. Dimulescu, J.C. Nicolau, A.J.M. Oude Ophuis, A. Cahn, O. Mosenzon, I. Gause-Nilsson, A.M. Langkilde, M.S. Sabatine, S.D. Wiviott, “Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial”, vol. 145 no. 21, pp. 1581–1591, May 2022. doi: 10.1161/CIRCULATIONAHA.121.058103 PMID: 35510542.FurtadoR.H.M.RazI.GoodrichE.L.MurphyS.A.BhattD.L.LeiterL.A.McGuireD.K.WildingJ.P.H.AylwardP.DalbyA.J.DellborgM.DimulescuD.NicolauJ.C.Oude OphuisA.J.M.CahnA.MosenzonO.Gause-NilssonI.LangkildeA.M.SabatineM.S.WiviottS.D.“Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial”1452115811591May202210.1161/CIRCULATIONAHA.121.058103PMID: 35510542.35510542Open DOISearch in Google Scholar
Kosiborod et al., “Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial”, Lancet Diabetes Endocrinol, vol. 9, pp. 586–94, 2021.Kosiborod“Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial”Lancet Diabetes Endocrinol958694202110.1016/S2213-8587(21)00180-7829480734302745Search in Google Scholar
Z.L. Cox, S.P. Collins, M. Aaron, G.A. Hernandez, A.T.M. Iii, B.T. Davidson, M. Fowler, C.J. Lindsell, F.E.H. Jr, C.A. Jenkins, C. Kampe, K.F. Miller, W.B. Stubblefield, J. Lindenfeld, “Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial”, Am Heart J, 232, pp. 116–124, Feb 2021. doi: 10.1016/j.ahj.2020.10.071 PMID: 33144086CoxZ.L.CollinsS.P.AaronM.HernandezG.A.IiiA.T.M.DavidsonB.T.FowlerM.LindsellC.J.JrF.E.H.JenkinsC.A.KampeC.MillerK.F.StubblefieldW.B.LindenfeldJ.“Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial”Am Heart J232116124Feb202110.1016/j.ahj.2020.10.071PMID: 3314408633144086Open DOISearch in Google Scholar
D. von Lewinski, M. Benedikt, N. Tripolt, M. Wallner, H. Sourij, E. Kolesnik, “Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients with acute myocardial infarction?”, Kardiol Pol, vol. 79 no. 5, pp.503–509, 2021. doi: 10.33963/KP.15969 PMID: 34125922von LewinskiD.BenediktM.TripoltN.WallnerM.SourijH.KolesnikE.“Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients with acute myocardial infarction?”Kardiol Pol795503509202110.33963/KP.15969PMID: 3412592234125922Open DOISearch in Google Scholar
L. Cavka, U. Bencak Ferko, N. Pitz, Z. Trpkovski, M. Lainscak, “Sodium-glucose cotransporter 2 inhibitor-induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction”, ESC Heart Fail, vol. 8 no. 4, pp. 2631–2636, August 2021. doi: 10.1002/ehf2.13452 PMID: 34102028 PMCID: PMC8318418CavkaL.Bencak FerkoU.PitzN.TrpkovskiZ.LainscakM.“Sodium-glucose cotransporter 2 inhibitor-induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction”ESC Heart Fail8426312636August202110.1002/ehf2.13452PMID: 34102028 PMCID: PMC8318418831841834102028Open DOISearch in Google Scholar
R. Wachter, M. Senni, J. Belohlavek, E. Straburzynska-Migaj, K.K. Witte, Z. Kobalava, C. Fonseca, E. Goncalvesova, Y. Cavusoglu, A. Fernandez, S. Chaaban, E. Bøhmer, A.C. Pouleur, C. Mueller, C. Tribouilloy, E. Lonn, J. A.L. Buraiki, J. Gniot, M. Mozheiko, M. Lelonek, A. Noè, H. Schwende, W. Bao, D. Butylin, D. Pascual-Figal, “TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study”, Eur J Heart Fail., vol. 21 no. 8, pp. 998–1007, August 2019. doi: 10.1002/ejhf.1498 PMID: 31134724WachterR.SenniM.BelohlavekJ.Straburzynska-MigajE.WitteK.K.KobalavaZ.FonsecaC.GoncalvesovaE.CavusogluY.FernandezA.ChaabanS.BøhmerE.PouleurA.C.MuellerC.TribouilloyC.LonnE.BuraikiJ. A.L.GniotJ.MozheikoM.LelonekM.NoèA.SchwendeH.BaoW.ButylinD.Pascual-FigalD.“TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study”Eur J Heart Fail.2189981007August201910.1002/ejhf.1498PMID: 3113472431134724Open DOISearch in Google Scholar
E.J. Velazquez, D.A. Morrow, A.D. DeVore, C.I. Duffy, A.P. Ambrosy, K. McCague, R. Rocha, E. Braunwald, “PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure”, N Engl J Med, vol. 380 no. 6, pp. 539–548, Feb 2019. doi: 10.1056/NEJMoa1812851 Erratum in: N Engl J Med. vol. 380 no. 11, p. 1090, March 2019. PMID: 30415601VelazquezE.J.MorrowD.A.DeVoreA.D.DuffyC.I.AmbrosyA.P.McCagueK.RochaR.BraunwaldE.“PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure”N Engl J Med3806539548Feb201910.1056/NEJMoa1812851Erratum in: N Engl J Med. vol. 380 no. 11, p. 1090, March 2019. PMID: 3041560130415601Open DOISearch in Google Scholar
D.Y. Chen, C.C. Chen, C.N. Tseng, S.W. Chen, S.H. Chang, W.K. Huang, M.S. Wen, M.J. Hsieh, I.C. Hsieh, “Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study”, EClinicalMedicine, 8;41:101149, Oct 2021. doi: 10.1016/j.eclinm.2021.101149 PMID: 34693232 PMCID: PMC8515399ChenD.Y.ChenC.C.TsengC.N.ChenS.W.ChangS.H.HuangW.K.WenM.S.HsiehM.J.HsiehI.C.“Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study”EClinicalMedicine841101149Oct202110.1016/j.eclinm.2021.101149PMID: 34693232 PMCID: PMC8515399851539934693232Open DOISearch in Google Scholar
T. Martyn et al., “Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy”, J Card Fail, vol. 27 no. 3, pp. 368–372, March 2021.MartynT.“Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy”J Card Fail273368372March202110.1016/j.cardfail.2020.12.01333358957Search in Google Scholar
J.S. Tran, O. Havakuk, J.M. McLeod, J. Hwang, H.Y. Kwong, D. Shavelle, M.R. Zile, U. Elkayam, M.W. Fong, L.P. Grazette, “Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction”, ESC Heart Fail, vol. 8 no. 2, pp. 1706–1710, April 2021. doi: 10.1002/ehf2.13225 PMID: 33522140 PMCID: PMC8006690TranJ.S.HavakukO.McLeodJ.M.HwangJ.KwongH.Y.ShavelleD.ZileM.R.ElkayamU.FongM.W.GrazetteL.P.“Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction”ESC Heart Fail8217061710April202110.1002/ehf2.13225PMID: 33522140 PMCID: PMC8006690800669033522140Open DOISearch in Google Scholar
M.A. Pfeffer et al., “Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction”, N Engl J Med, 385, pp. 1845–1855, 2021. doi: 10.1056/NEJMoa2104508PfefferM.A.“Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction”N Engl J Med38518451855202110.1056/NEJMoa210450834758252Open DOISearch in Google Scholar
D. Carballo, J. Stirnemann, N. Garin, C. Marti, J. Serratrice, S. Carballo, “Eligibility for sacubitril-valsartan in patients with acute decompensated heart failure”, ESC Heart Fail, vol. 7 no. 3, pp. 1282–1290, March 2020. doi: 10.1002/ehf2.12676 PMID: 32167679 PMCID: PMC7261587CarballoD.StirnemannJ.GarinN.MartiC.SerratriceJ.CarballoS.“Eligibility for sacubitril-valsartan in patients with acute decompensated heart failure”ESC Heart Fail7312821290March202010.1002/ehf2.12676PMID: 32167679 PMCID: PMC7261587726158732167679Open DOISearch in Google Scholar
S. Carballo, J. Stirnemann, N. Garin, P. Darbellay Farhoumand, J. Serratrice, D. Carballo, “Prognosis of patients eligible for dapagliflozin in acute heart failure”, Eur J Clin Invest, vol. 50 no. 6, June 2020. doi: 10.1111/eci.13245 PMID: 32306388CarballoS.StirnemannJ.GarinN.Darbellay FarhoumandP.SerratriceJ.CarballoD.“Prognosis of patients eligible for dapagliflozin in acute heart failure”Eur J Clin Invest506June202010.1111/eci.13245PMID: 3230638832306388Open DOISearch in Google Scholar
M. Fudim, S. Sayeed, H. Xu, R.A. Matsouaka, P.A. Heidenreich, E.J. Velazquez, C.W. Yancy, G.C. Fonarow, A.F. Hernandez, A.D. DeVore, “Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction”, Circ Heart Fail., vol. 13 no. 4, April 2020. doi: 10.1161/CIRCHEARTFAILURE.119.006645 PMID: 32248695 PMCID: PMC8819257FudimM.SayeedS.XuH.MatsouakaR.A.HeidenreichP.A.VelazquezE.J.YancyC.W.FonarowG.C.HernandezA.F.DeVoreA.D.“Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction”Circ Heart Fail.134April202010.1161/CIRCHEARTFAILURE.119.006645PMID: 32248695 PMCID: PMC8819257881925732248695Open DOISearch in Google Scholar
H. Kurdi, P. Shah, S. Barker, D. Harris, B. Dicken, C. Edwards, G. Jenkins, “Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure”, Br J Cardiol, vol. 28 no. 2, April 2021. doi: 10.5837/bjc.2021.018 PMID: 35747454 PMCID: PMC8822528KurdiH.ShahP.BarkerS.HarrisD.DickenB.EdwardsC.JenkinsG.“Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure”Br J Cardiol282April202110.5837/bjc.2021.018PMID: 35747454 PMCID: PMC8822528882252835747454Open DOISearch in Google Scholar
N.S. Bassi, B. Ziaeian, C.W. Yancy, G.C. Fonarow, “Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. JAMA Cardiol”, vol. 5 no. 8, pp. 948–951, Aug 2020. doi: 10.1001/jamacardio.2020.0898 PMID: 32374344 PMCID: PMC7203666BassiN.S.ZiaeianB.YancyC.W.FonarowG.C.Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart FailureJAMA Cardiol58948951Aug202010.1001/jamacardio.2020.0898PMID: 32374344 PMCID: PMC7203666720366632374344Open DOISearch in Google Scholar
A. Ntalianis, C. Chrysohoou, G. Giannakoulas, G. Giamouzis, A. Karavidas, A. Naka, C.H. Papadopoulos, S. Patsilinakos, J. Parissis, D. Tziakas, J. Kanakakis, “Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper”, Heart Fail Rev, vol. 27 no. 1, pp. 1–13, May 2021. doi: 10.1007/s10741-021-10115-8 PMID: 33931815 PMCID: PMC8087533NtalianisA.ChrysohoouC.GiannakoulasG.GiamouzisG.KaravidasA.NakaA.PapadopoulosC.H.PatsilinakosS.ParissisJ.TziakasD.KanakakisJ.“Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper”Heart Fail Rev271113May202110.1007/s10741-021-10115-8PMID: 33931815 PMCID: PMC8087533808753333931815Open DOISearch in Google Scholar
D. Tomasoni, G.C. Fonarow, M. Adamo, S.D. Anker, J. Butler, A.J.S. Coats, G. Filippatos, S.J. Greene, T.A. McDonagh, P. Ponikowski, G. Rosano, P. Seferovic, M. Vaduganathan, A.A. Voors, M. Metra, “Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction”, Eur J Heart Fail, vol. 24, no. 3, pp. 431–441, March 2022. doi: 10.1002/ejhf.2397 PMID: 34894038; PMCID: PMC9303969TomasoniD.FonarowG.C.AdamoM.AnkerS.D.ButlerJ.CoatsA.J.S.FilippatosG.GreeneS.J.McDonaghT.A.PonikowskiP.RosanoG.SeferovicP.VaduganathanM.VoorsA.A.MetraM.“Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction”Eur J Heart Fail24,3431441March202210.1002/ejhf.2397PMID: 34894038; PMCID: PMC9303969930396934894038Open DOISearch in Google Scholar
A. Tymińska, K. Ozierański, M. Grabowski, G. Opolski, P. Balsam, “Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure”, Cardiol J, vol. 27 no. 5, pp. 625–632, 2020. doi: 10.5603/CJ.a2020.0094 PMID: 32648251 PMCID: PMC8078992TymińskaA.OzierańskiK.GrabowskiM.OpolskiG.BalsamP.“Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure”Cardiol J275625632202010.5603/CJ.a2020.0094PMID: 32648251 PMCID: PMC8078992807899232648251Open DOISearch in Google Scholar
E. Gayat, M. Arrigo, S. Littnerova, N. Sato, J. Parenica, S. Ishihara, J. Spinar, C. Muller, V.P. Harjola, J. Lassus, O. Miro, A.P. Maggioni, K.F. AlHabib, D.J. Choi, J.J. Park, Y. Zhang, J. Zhang, J.L. Januzzi, K. Kajimoto Jr., A. Cohen-Solal, A. Mebazaa, G. Network, “Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study”, Eur J Heart Fail 20:345354, 2018.GayatE.ArrigoM.LittnerovaS.SatoN.ParenicaJ.IshiharaS.SpinarJ.MullerC.HarjolaV.P.LassusJ.MiroO.MaggioniA.P.AlHabibK.F.ChoiD.J.ParkJ.J.ZhangY.ZhangJ.JanuzziJ.L.KajimotoK.Jr.Cohen-SolalA.MebazaaA.NetworkG.“Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study”Eur J Heart Fail20345354201810.1002/ejhf.93228849606Search in Google Scholar
J.J.V. McMurray, S.D. Solomon, S.E. Inzucchi, L. Køber, M.N. Kosiborod, F.A. Martinez, P. Ponikowski, M.S. Sabatine, I.S. Anand, J. Belohlavek, M. Böhm, C-E Chiang, V.K. Chopra, R.A. de Boer, A.S. Desai, M. Diez, J. Drozdz, A. Dukat, J. Ge, J.G. Howlett, T. Katova, M. Kitakaze, C.E.A. Ljungman, B. Merkely, J.C. Nicolau, E. O’Meara, M.C. Petrie, P.N. Vinh, M. Schou, S. Tereshchenko, S. Verma, C. Held, D.L. DeMets, K.F. Docherty, P.D. Jhund, O. Bengtsson, M. Sjöstrand, A.M. Langkilde, DAPA-HF Trial Committees and Investigators, “Dapagliflozin in patients with heart failure and reduced ejection fraction”, N Engl J Med, 2019. 381:19952008.McMurrayJ.J.V.SolomonS.D.InzucchiS.E.KøberL.KosiborodM.N.MartinezF.A.PonikowskiP.SabatineM.S.AnandI.S.BelohlavekJ.BöhmM.ChiangC-EChopraV.K.de BoerR.A.DesaiA.S.DiezM.DrozdzJ.DukatA.GeJ.HowlettJ.G.KatovaT.KitakazeM.LjungmanC.E.A.MerkelyB.NicolauJ.C.O’MearaE.PetrieM.C.VinhP.N.SchouM.TereshchenkoS.VermaS.HeldC.DeMetsD.L.DochertyK.F.JhundP.D.BengtssonO.SjöstrandM.LangkildeA.M.DAPA-HF Trial Committees and Investigators“Dapagliflozin in patients with heart failure and reduced ejection fraction”N Engl J Med20193811995200810.1056/NEJMoa191130331535829Search in Google Scholar
S. Yusuf, M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J. McMurray, E.L. Michelson, B. Olofsson, J. Ostergren, CHARM Investigators and Committees, “Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial”, Lancet, 2003. 362:777781YusufS.PfefferM.A.SwedbergK.GrangerC.B.HeldP.McMurrayJ.J.MichelsonE.L.OlofssonB.OstergrenJ.CHARM Investigators and Committees“Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial”Lancet200336277778110.1016/S0140-6736(03)14285-713678871Search in Google Scholar
B. Pitt, M.A. Pfeffer, S.F. Assmann, R. Boineau, I.S. Anand, B. Claggett, N. Clausell, A.S. Desai, R. Diaz, J.L. Fleg, I. Gordeev, B. Harty, J.F. Heitner, C.T. Kenwood, E.F. Lewis, E. O’Meara, J.L. Probstfield, T. Shaburishvili, S.J. Shah, S.D. Solomon, N.K. Sweitzer, S. Yang, S.M. McKinlay, TOPCAT Investigators, “Spironolactone for heart failure with preserved ejection fraction”, N Engl J Med, 2014. 370:13831392.PittB.PfefferM.A.AssmannS.F.BoineauR.AnandI.S.ClaggettB.ClausellN.DesaiA.S.DiazR.FlegJ.L.GordeevI.HartyB.HeitnerJ.F.KenwoodC.T.LewisE.F.O’MearaE.ProbstfieldJ.L.ShaburishviliT.ShahS.J.SolomonS.D.SweitzerN.K.YangS.McKinlayS.M.TOPCAT Investigators“Spironolactone for heart failure with preserved ejection fraction”N Engl J Med20143701383139210.1056/NEJMoa131373124716680Search in Google Scholar
S.D. Solomon, J.J.V. McMurray, I.S. Anand, J. Ge, C.S.P. Lam, A.P. Maggioni, F. Martinez, M. Packer, M.A. Pfeffer, B. Pieske, M.M. Redfield, J.L. Rouleau, D.J. van Veldhuisen, F. Zannad, M.R. Zile, A.S. Desai, B. Claggett, P.S. Jhund, S.A. Boytsov, J. Comin-Colet, J. Cleland, H.D. Dungen, E. Goncalvesova, T. Katova, J.F. Kerr Saraiva, M. Lelonek, B. Merkely, M. Senni, S.J. Shah, J. Zhou, A.R. Rizkala, J. Gong, V.C. Shi, M.P. Lefkowitz, PARAGON-HF Investigators and Committees, “Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction”, N Engl J Med, 2019. 381:16091620SolomonS.D.McMurrayJ.J.V.AnandI.S.GeJ.LamC.S.P.MaggioniA.P.MartinezF.PackerM.PfefferM.A.PieskeB.RedfieldM.M.RouleauJ.L.van VeldhuisenD.J.ZannadF.ZileM.R.DesaiA.S.ClaggettB.JhundP.S.BoytsovS.A.Comin-ColetJ.ClelandJ.DungenH.D.GoncalvesovaE.KatovaT.Kerr SaraivaJ.F.LelonekM.MerkelyB.SenniM.ShahS.J.ZhouJ.RizkalaA.R.GongJ.ShiV.C.LefkowitzM.P.PARAGON-HF Investigators and Committees“Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction”N Engl J Med20193811609162010.1056/NEJMoa190865531475794Search in Google Scholar